BMS stops developing new antiviral drugs and cancels 100 related positions

Bristol Myers Squibb said on June 25 that it would stop developing new antiviral drugs and would remove 100 related positions The company said its early projects on hepatitis B and HIV would also be terminated Squibb said the decision would not affect products already on the market and ongoing clinical virology projects The company is applying to the United States for approval of its experimental hepatitis C drug daclatasvir On March 12, 2015, FDA has accepted the new drug application of its leading candidate product daclatasvir The drug is used in combination with sowaldi of Gilead science for the treatment of genotype 3 chronic hepatitis C In November 2014, the joint scheme of daclatasvir and the company's drug asunaprevir submitted by the company was withdrawn by the agency due to the possible competition for more effective drugs in the market So the FDA asked the company to further collect data from daclatasvirs to meet the ally test Subsequently, Bristol Myers Squibb is committed to testing the efficacy of daclatasvirs combined with sovaldi in the treatment of genotype 3 hepatitis C The compound has been approved for the same indication in the European Union under the brand name daklnza Bristol Myers Squibb's share price edged up to $67.47 when it was listed on the New York Stock Exchange The two closed units and about 200 employees of Bristol Myers Squibb's New Jersey company will be reassigned to the new unit, which will focus on exploring genetic diseases, molecular discovery technology and platform chemistry exploration, the company said Another 500 warringford employees will move to a new, yet to be determined location in Connecticut At the same time, Bristol Myers Squibb is expected to establish a research institute in Cambridge, Massachusetts in 2018 In addition, the research and development site in the Woodside Science Park in the San Francisco Bay area will be expanded, and the laboratory and office space will be expanded by 61000 square feet, which is scheduled to be completed next year Workplace transformation "enables companies and our scientists to have an appropriate position in the world's first-class science, innovation and business operations dynamic ecosystem center," said cuss, chief science officer of Bristol Myers Squibb The shift to life science research hubs such as Cambridge and San Francisco has become a feature of the biopharmaceutical industry in recent years An example of this is AstraZeneca's downsizing of its R & D business in Cheshire in order to build and operate in Cambridge, which has formed a golden triangle of life sciences in the UK with London and Oxford BMS bet on cancer immunotherapy in late June, opdivo (nivolumab), a PD-1 immunotherapy developed by BMS, was approved by the European Union to treat advanced melanoma, making it the first PD-1 immunotherapy to open the European market, and the first PD-1 immunotherapy to successfully win the three major markets of Japan, the United States and the European Union At the same time, it is expected that opdivo lung cancer application will be approved in July, becoming the first PD-1 immunotherapy for non-small cell lung cancer in European market Another thing to look forward to is that the first-line application of opdivo + yevoy for advanced melanoma, which has attracted the attention of the industry, is likely to be approved by the FDA in September this year At present, the combination has been supported by the FDA Expert Committee In clinical trials, compared with yevoy single drug, combination therapy has achieved extremely high objective remission rate (61% vs 11%) and complete remission rate (22% vs 0%), and the risk of disease deterioration or death has been reduced by 60%; the efficacy of combination therapy has never been stronger The industry believes that this program will provide an extremely important first-line treatment option for advanced melanoma, and once again prove the great potential of different immunotherapy combinations in the clinical treatment of tumor [this article is organized by new drug collection according to the dingxiangyuan, Biovalley and foreign media] http://